Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as EG-70 (phase 1)
EG-70 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| EG-70 (phase 1) | DRUG | Patients will receive up to four cycles of EG-70 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes.One cycle lasts approximately 12 weeks and consists of either a 2-dose (Day 1 and Day 8) or 4-dose (Day 1, Day 8, Day 29 and Day 36) regimen. |
| EG-70 (phase 2) | DRUG | Patients will receive during Treatment Period, up to 4 cycles of EG-70 at the RP2D defined in Phase 1 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes. One cycle lasts approximately 12 weeks. For Maintenance treatment 2 doses of EG-70 will be administered as a bladder instillation per 12-week cycle. |
EG-70 is being developed for superficial bladder cancer, including non-muscle invasive bladder cancer with carcinoma in situ. It is an investigational therapy studied in patients who are BCG-unresponsive, high-risk and incompletely treated with BCG, or BCG-naive. It has not been approved for any use.
EG-70 is being developed by enGene Holdings Inc., which trades under the ticker ENGN. The company is the sponsor of the clinical program evaluating the asset in bladder cancer.
EG-70 is in Phase 2 development. Its single clinical trial is registered as a Phase 1/Phase 2 study, and the program has reached the Phase 2 stage overall. EG-70 remains investigational and is not approved.
EG-70 is being evaluated in the LEGEND Study, registered as NCT04752722. This recruiting Phase 1/Phase 2 trial plans to enroll 350 patients with superficial bladder cancer and non-muscle invasive bladder cancer with carcinoma in situ. It is an uncontrolled study without randomization or double blinding.
Yes. EG-70 (phase 1) is an alternative name used for EG-70, the same investigational asset from enGene Holdings Inc. Searches for either name refer to the same bladder cancer program.